ATE479434T1 - Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine - Google Patents

Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine

Info

Publication number
ATE479434T1
ATE479434T1 AT07750530T AT07750530T ATE479434T1 AT E479434 T1 ATE479434 T1 AT E479434T1 AT 07750530 T AT07750530 T AT 07750530T AT 07750530 T AT07750530 T AT 07750530T AT E479434 T1 ATE479434 T1 AT E479434T1
Authority
AT
Austria
Prior art keywords
dyhydrodiazepines
usable
protein kinase
kinase inhibitors
inhibitors
Prior art date
Application number
AT07750530T
Other languages
German (de)
English (en)
Inventor
Jean Damien-Charrier
David Kay
Ronald Knegtel
Heather Twin
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE479434T1 publication Critical patent/ATE479434T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07750530T 2006-02-14 2007-02-13 Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine ATE479434T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77299206P 2006-02-14 2006-02-14
US83137106P 2006-07-17 2006-07-17
US84935306P 2006-10-04 2006-10-04
US87620606P 2006-12-21 2006-12-21
PCT/US2007/003699 WO2007095188A2 (en) 2006-02-14 2007-02-13 Dihydrodiazepines useful as inhibitors of protein kinases

Publications (1)

Publication Number Publication Date
ATE479434T1 true ATE479434T1 (de) 2010-09-15

Family

ID=38330249

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07750530T ATE479434T1 (de) 2006-02-14 2007-02-13 Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine

Country Status (15)

Country Link
US (4) US7622463B2 (enExample)
EP (1) EP1983987B1 (enExample)
JP (2) JP5243970B2 (enExample)
KR (1) KR20080095902A (enExample)
AR (1) AR059505A1 (enExample)
AT (1) ATE479434T1 (enExample)
AU (1) AU2007215221C1 (enExample)
CA (1) CA2652648C (enExample)
DE (1) DE602007008837D1 (enExample)
IL (1) IL193240A0 (enExample)
NO (1) NO20083918L (enExample)
NZ (1) NZ570530A (enExample)
RU (1) RU2475488C2 (enExample)
TW (1) TW200804389A (enExample)
WO (1) WO2007095188A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
CN101636399B (zh) * 2007-03-22 2012-04-18 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
PL2168966T3 (pl) * 2007-06-15 2017-06-30 Msd K.K. Pochodna bicykloaniliny
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
BRPI0817315A2 (pt) 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
CN101878216B (zh) * 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2215091B1 (en) * 2007-12-04 2016-03-30 Nerviano Medical Sciences S.r.l. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2009153197A1 (en) 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
EP2318412B1 (en) 2008-06-23 2013-08-14 Vertex Pharmceuticals Incorporated Protein kinase inhibitors
CA2728729C (en) 2008-06-23 2016-09-27 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US8049005B2 (en) 2009-03-31 2011-11-01 Arqule, Inc. Substituted tetrahydropyrazolo-pyrido-azepine compounds
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
SG179207A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
MX2012003484A (es) 2009-09-25 2012-04-20 Vertex Pharma Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
CA2803446C (en) 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
EP2970317A4 (en) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
HUE038820T2 (hu) 2013-11-13 2018-11-28 Vertex Pharma Eljárás influenzavírusok replikációjának inhibitorai elõállítására
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015117083A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
GB201411581D0 (en) * 2014-06-30 2014-08-13 Inst Europ Di Oncologia S R L Compounds inhibiting the enzyme monopolar spindle 1 kinase, pharmaceutical compositions and uses thereof
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CA2968464A1 (en) 2014-11-25 2016-06-02 Bayer Pharma Aktiengesellschaft Substituted pyridobenzodiazepinone-derivatives and use thereof
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
KR102734259B1 (ko) 2021-03-04 2024-11-27 한양대학교 에리카산학협력단 피리디닐 피라졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
US12552768B2 (en) 2021-03-04 2026-02-17 Industry-University Cooperation Foundation Pyridinylpyrazole derivative or pharmaceutically acceptable salt thereof and use thereof
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR102696521B1 (ko) 2021-11-24 2024-08-20 한양대학교 에리카산학협력단 이속사졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5638032B2 (enExample) 1972-08-31 1981-09-03
US3880855A (en) * 1973-04-16 1975-04-29 Bristol Myers Co 5,6-DIHYDRO-11-H-pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines
US3872122A (en) * 1973-04-16 1975-03-18 Bristol Myers Co 11 H-Pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines
JPS51110202A (en) 1975-03-24 1976-09-29 Susumu Nojima Denwakyono hyojisochi
GB8927872D0 (en) 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JP2003509425A (ja) 1999-09-15 2003-03-11 ワーナー−ランバート・カンパニー キナーゼ阻害剤としてのプテリジノン
HK1053831A1 (zh) * 1999-09-17 2003-11-07 Basf Aktiengesellschaft 作为治疗药物的激酶抑制剂
BR0015995A (pt) 1999-11-30 2002-08-06 Pfizer Prod Inc Compostos 2,4-diaminopirimidina úteis como imunossupressores
US7101869B2 (en) * 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
UY27427A1 (es) 2001-09-04 2003-03-31 Boehringer Ingelheim Pharma Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
DE50307267D1 (de) 2003-02-26 2007-06-21 Boehringer Ingelheim Pharma Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
BRPI0817315A2 (pt) 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
JP4941835B2 (ja) 2007-09-28 2012-05-30 Ｔｏｔｏ株式会社 キャビネット及びキャビネットの施工方法
JP5035192B2 (ja) 2008-09-19 2012-09-26 コニカミノルタアドバンストレイヤー株式会社 駆動機構、駆動装置

Also Published As

Publication number Publication date
JP2013067666A (ja) 2013-04-18
AU2007215221B2 (en) 2013-01-17
US8022202B2 (en) 2011-09-20
CA2652648C (en) 2016-10-25
TW200804389A (en) 2008-01-16
AR059505A1 (es) 2008-04-09
CA2652648A1 (en) 2007-08-23
US20140038935A1 (en) 2014-02-06
JP5243970B2 (ja) 2013-07-24
NZ570530A (en) 2011-09-30
DE602007008837D1 (de) 2010-10-14
RU2475488C2 (ru) 2013-02-20
US20100190765A1 (en) 2010-07-29
US8394952B2 (en) 2013-03-12
KR20080095902A (ko) 2008-10-29
WO2007095188A3 (en) 2007-10-25
WO2007095188A2 (en) 2007-08-23
AU2007215221A1 (en) 2007-08-23
US7622463B2 (en) 2009-11-24
JP2009526849A (ja) 2009-07-23
IL193240A0 (en) 2009-08-03
HK1129298A1 (en) 2009-11-27
US20080167289A1 (en) 2008-07-10
RU2008136854A (ru) 2010-03-20
AU2007215221C1 (en) 2013-05-30
EP1983987B1 (en) 2010-09-01
NO20083918L (no) 2008-11-12
US20120149898A1 (en) 2012-06-14
EP1983987A2 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
FR21C1019I2 (fr) Inhibiteurs de kinase de type biaryl-meta-pyrimidine
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI0910668A2 (pt) inibidores de proteína quinases
ATE510839T1 (de) Benzofuropyrimidinone als proteinkinase-hemmer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
EP2040546A4 (en) tyrosine kinase inhibitor
BRPI0719797A2 (pt) compostos e composições como inibidores de proteína cinase
CR10755A (es) Compounds and compositions as protein kinase inhibitors
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
ATE492544T1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2046826T3 (da) Exendin-fusionsproteiner
ATE501142T1 (de) Als proteinkinaseinhibitoren geeignete phenylacetamide
ATE512972T1 (de) Pyrrolopyrazole als wirksame kinaseinhibitoren
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
BRPI0717317A2 (pt) Modularoes da proteína cinase triazalopiridazina
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0716781A2 (pt) Inibidores da quinase
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
DK2035385T3 (da) Inhibitorer af akt (proteinkinase B)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1983987

Country of ref document: EP